Bispecific Antibodies in B-Cell Lymphomas: Mechanisms, Efficacy, Toxicity, and Management - PubMed
7 hours ago
- #Bispecific Antibodies
- #B-cell Lymphomas
- #Immunotherapy
- Bispecific antibodies (BsAbs) like mosunetuzumab, epcoritamab, odronextamab, and glofitamab are pivotal in treating relapsed/refractory B-cell lymphomas.
- These CD20 × CD3 BsAbs link malignant B-cells and T-cells, inducing targeted tumor lysis by activating T-cells and bypassing MHC presentation.
- BsAbs show high overall and complete response rates in diffuse large B-cell lymphoma and follicular lymphoma.
- Key toxicities include Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), managed with tocilizumab and corticosteroids.
- BsAb therapy increases susceptibility to infections, necessitating antimicrobial prophylaxis and immunoglobulin supplements.
- Despite their 'off-the-shelf' advantage, balancing efficacy with toxicity management is crucial for optimal patient outcomes.